Menu
Search
|

Menu

Close
X

TESARO Inc TSRO.OQ (NASDAQ Stock Exchange Global Select Market)

49.62 USD
-- (--)
As of Jun 22
chart
Previous Close 49.62
Open --
Volume --
3m Avg Volume 448,059
Today’s High --
Today’s Low --
52 Week High 153.98
52 Week Low 38.45
Shares Outstanding (mil) 54.18
Market Capitalization (mil) 6,492.51
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.06 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY18
50
FY17
223
FY16
58
FY15
4
EPS (USD)
FY18
-2.981
FY17
-9.176
FY16
-7.819
FY15
-6.272
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.74
Price to Sales (TTM)
vs sector
160.34
5.71
Price to Book (MRQ)
vs sector
16.23
5.37
Price to Cash Flow (TTM)
vs sector
--
23.32
Total Debt to Equity (MRQ)
vs sector
34.37
16.46
LT Debt to Equity (MRQ)
vs sector
34.37
12.19
Return on Investment (TTM)
vs sector
-125.62
14.38
Return on Equity (TTM)
vs sector
-185.12
16.08

EXECUTIVE LEADERSHIP

David Mott
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Mary Hedley
President, Chief Operating Officer, Director, Since 2014
Salary: $584,462.00
Bonus: --
Leon Moulder
Chief Executive Officer, Director, Since 2010
Salary: $639,385.00
Bonus: --
Timothy Pearson
Chief Financial Officer, Executive Vice President, Principal Accounting Officer, Since 2017
Salary: $402,058.00
Bonus: --
Jeffrey Hanke
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2015
Salary: $411,815.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1000 Winter St Ste 3300
WALTHAM   MA   02451-1230

Phone: +1339.9700900

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

SPONSORED STORIES